---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Executive summary: Disease burden"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Disease burden. Topics: Summary: incidence and prevalence; Summary: survival and mortality; Summary: morbidity, quality of life, and resource use. 3 evidence topics quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary/disease-burden"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Executive summary: Disease burden

<a id="heading-1.1.1"></a>

## 1.1.1 Burden of Tumor hyperinsulinism

<a id="topic-1.1.1-1"></a>

### Summary: incidence and prevalence

- Population-based incidence of insulinoma was 0.6 per million adults per year in Finland from 1980 to 2010 (0.9 per million per year in the 2000s), 1.3 cases per million per year in Western Sweden from 2002 to 2019, 4 cases per 1 million person-years in Olmsted County, Minnesota, during the last 2 decades of the study period, and 3.27 (95% CI, 2.93-3.61) per million adults per year in a Japanese national inpatient database in 2012. A clinical review reports a range of 0.7 to 4 cases per million per year.
- Malignant or metastatic disease made up 14% (malignant) and 11% (distant metastases) of 79 Finnish cases, 16% (metastatic) of 37 Swedish cases, and 5.8% (malignant) of the 224 Mayo Clinic cases. A review places 10% to 15% of insulinomas in the aggressive category. The crude annual incidence of malignant insulinoma in the SEER registries from 1973 to 2015 (121 patients) ranged from 0.0 to 0.27 cases per million person years.
- A Japanese nationwide survey of patients treated in 2017 to 2018 identified 205 patients with insulinoma (118 benign, 18 malignant, 69 unknown subtype) and estimated a prevalence of 0.16 per 100,000 population.
- No population-based study of non-islet cell tumor hypoglycemia (NICTH) was identified. A systematic review cites an incidence rate of one per million person-years and estimates NICTH to be four times less prevalent than insulinoma.
- The manufacturer estimates the U.S. “immediately addressable incidence market” for tumor hyperinsulinism at approximately 3,000 patients per year (Form 10-K, September 2026) and approximately 4,000 patients per year (Form 10-Q, November 2026), and gives a point-in-time prevalence as of October 2026 of about 2,500 malignant insulinoma and about 1,500 NICTH patients from a claims database.

Source: [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/); [Svensson et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9210785/); [Service et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/1677058/); [Kurakawa et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34343300/); [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/); [Sada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7678752/); [Yamada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7232294/); [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/); [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm); [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm); [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-1.1.1-2"></a>

### Summary: survival and mortality

- A review reports 5-year survival of 94% to 100% for indolent insulinoma and 24% to 67% for aggressive insulinoma.
- In a Finnish nationwide cohort, median overall survival with non-metastatic insulinoma was 27.5 years and did not differ significantly from matched controls (33.2 years; HR 1.5, P = 0.128); with metastatic insulinoma it was 3.4 years (HR 5.1, P = 0.001). Perioperative mortality was 2.7%.
- In the Mayo Clinic cohort, survival with malignant insulinoma was 29% at 10 years postoperatively against 88% expected. At one institution, 5-year overall survival was 66.8% for 51 patients with malignant insulinoma and 95.4% for 260 patients with benign insulinoma.
- In the SEER malignant insulinoma cohort, median overall survival was 143 months, with 5- and 10-year overall survival of 58% and 55%, and 5-year overall survival was 84% with surgery and 14% without. In an Italian series of 31 patients with malignant insulinoma, 5-year survival was 62%.
- In a systematic review of published NICTH cases with outcomes (n = 223), the recovery rate was 77% and mortality 23%.

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/); [Peltola et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8784472/); [Service et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/1677058/); [Sada et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32873371/); [Sada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7678752/); [Veltroni et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32061159/); [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="topic-1.1.1-3"></a>

### Summary: morbidity, quality of life, and resource use

- Compared with matched controls, Finnish insulinoma patients had a higher long-term incidence of atrial fibrillation (rate ratio 2.07) and intestinal obstruction (rate ratio 18.65). In a Japanese nationwide survey, neurological impairment was present in 22 patients (10.7%) with insulinoma (seven with dementia, seven with epilepsy), diabetes followed pancreatectomy in 25 patients (15.8%), and impaired quality of life was reported in 9 of 29 patients with residual hypoglycemia. Before surgery, 18 of 34 patients (53%) screened positive for cognitive impairment in one prospective study.
- In the published expanded access series of refractory malignant insulin-secreting tumors, 6 of 8 individuals were hospitalized at entry (median, 28 days; range, 4-66 days), 4 had an ECOG score of 3, and 2 were under hospice consideration. The manufacturer states that tumor-directed therapies were often deferred because of debilitating hypoglycemia.
- Patients surgically cured of insulinoma had a mean 15D score of 0.930 against 0.903 in the general population a median of 13 years after surgery. No quality of life data were identified for NICTH.
- No cost-of-illness or claims-based cost study of insulinoma or NICTH was identified. Reported resource use includes hospital stays of 11.1 days after surgical resection and 3.0 days after endoscopic ultrasound-guided radiofrequency ablation, and an average postoperative stay of 9 days in a single-center series.

Source: [Peltola et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8784472/); [Yamada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7232294/); [Dai et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31292840/); [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/); [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm); [Peltola et al. (2021a)](https://pubmed.ncbi.nlm.nih.gov/32974918/); [Crinò et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36871765/); [Nockel et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8058619/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
